Cachexia News and Research

RSS
Cachexia is a condition which denotes the excessive loss of weight. It occurs because of the depletion of adipose tissue and muscle mass in people who are not trying to lose weight.
GTx third quarter net loss decreases to $8.6 million

GTx third quarter net loss decreases to $8.6 million

Cachexia reduces function and changes muscle structure of heart in mice with colon cancer

Cachexia reduces function and changes muscle structure of heart in mice with colon cancer

Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program

Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program

Nutritional recommendations for management of sarcopenia published

Nutritional recommendations for management of sarcopenia published

Muscle mass plays key role in cancer survival: Research

Muscle mass plays key role in cancer survival: Research

GTx second-quarter net loss increases to $12.9 million

GTx second-quarter net loss increases to $12.9 million

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Ostarine increases muscle mass and strength in postmenopausal women: Study

Ostarine increases muscle mass and strength in postmenopausal women: Study

Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting

Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

Alder Biopharmaceuticals reports positive data from ALD518 Phase 2a clinical trial for NSCLC

Alder Biopharmaceuticals reports positive data from ALD518 Phase 2a clinical trial for NSCLC

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer

Palatin Technologies granted patent relating to small molecule compounds that bind to melanocortin receptors

Palatin Technologies granted patent relating to small molecule compounds that bind to melanocortin receptors

GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11.3M in 2009

GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11.3M in 2009

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

GTx reacquires full rights to Ostarine

GTx reacquires full rights to Ostarine

Study shows ghrelin prevents acute liver damage, reduces oxidative stress and inflammation

Study shows ghrelin prevents acute liver damage, reduces oxidative stress and inflammation

Allen & Caron selected as Ohr Pharmaceutical's agency for investor relations

Allen & Caron selected as Ohr Pharmaceutical's agency for investor relations

Non-clinical data of CK-2017357 presented by Cytokinetics

Non-clinical data of CK-2017357 presented by Cytokinetics

Ohr Pharmaceutical to present interim data from ongoing Phase II clinical trial of OHR/AVR118

Ohr Pharmaceutical to present interim data from ongoing Phase II clinical trial of OHR/AVR118